Review: Oral and intravenous antibiotics do not differ for effectiveness in febrile neutropenic patients with cancer

March 2005
ACP Journal Club;Mar/Apr2005, Vol. 142 Issue 2, p32
Academic Journal
The article cites a survey of studies related to the safety and effectiveness of oral and intravenous (IV) antibiotics in febrile neutropenic patients with cancer. Randomized controlled trials (RCTs) that compared any oral antibiotic with any IV antibiotic in patients with cancer and chemotherapy-induced neutropenia or patients with cancer who had bone marrow transplantation and presented with fever .In febrile neutropenic patients with cancer, oral and intravenous antibiotics do not differ for mortality, treatment failure, or adverse events.


Related Articles

  • Improved survival of critically ill cancer patients with septic shock. Larché, Jérôme; Azoulay, Élie; Fieux, Fabienne; Mesnard, Laurent; Moreau, Delphine; Thiery, Guillaume; Darmon, Michaël; Le Gall, Jean-Roger; Schlemmer, Benoît; Larché, Jérôme; Azoulay, Elie; Darmon, Michaël; Schlemmer, Benoît // Intensive Care Medicine;Oct2003, Vol. 29 Issue 10, p1688 

    Objective: To identify predictors of 30-day mortality in critically ill cancer patients with septic shock.Design: Retrospective study over a 6-year period.Setting: Twelve-bed medical intensive care unit (ICU).Patients: Eighty-eight patients (55...

  • Ventilator-associated pneumonia: caveats for benchmarking. Eggimann, Philippe; Hugonnet, Stéphane; Sax, Hugo; Touveneau, Sylvie; Chevrolet, Jean-Claude; Pittet, Didier; Hugonnet, Stéphane // Intensive Care Medicine;Nov2003, Vol. 29 Issue 11, p2086 

    Objective: To determine the influence of using different denominators on risk estimates of ventilator-associated pneumonia (VAP).Design and Setting: Prospective cohort study in the medical ICU of a large teaching hospital.Patients: All consecutive patients...

  • Symposium Highlights Challenges and Victories After Transplant.  // Blood & Marrow Transplant Newsletter;Nov2008, Vol. 18 Issue 3, p5 

    The article discusses the highlights of Celebrating a Second Chance at Life survivorship symposium held in Dallas, Texas from September 20-21, 2008. Transplant survivors from India, South America and Australia participated in the symposium which was designed to help survivors and their families...

  • Granulocyte colony-stimulating factor (filgrastim) in chemotherapy-induced febrile neutropenia. Advani, S. H.; Achreckar, Suvarna; Thomas, Dennis; Krishnankutty, Binny // Indian Journal of Medical & Paediatric Oncology;Jul-Sep2010, Vol. 31 Issue 3, p125 

    Background: The use of granulocyte colony-stimulating factors to treat patients with chemotherapy-induced neutropenia is well accepted. To assess whether administration of filgrastim along with standard empiric antibiotic therapy is beneficial for patients with chemotherapy-induced febrile...

  • A prognostic model for prolonged event-free survival after autologous or allogeneic blood or marrow transplantation for relapsed and refractory Hodgkin's disease. Hahn, T.; Benekli, M.; Wong, C.; Moysich, K. B.; Hyland, A.; Michalek, A. M.; Alam, A.; Baer, M. R.; Bambach, B.; Czuczman, M. S.; Wetzler, M.; Becker, J. L.; McCarthy, P. L. // Bone Marrow Transplantation;Mar2005, Vol. 35 Issue 6, p557 

    Summary:There are several prognostic models for Hodgkin's disease (HD) patients, but none evaluating patient characteristics at time of blood and marrow transplantation (BMT). We developed a prognostic model for event-free survival (EFS) post-BMT based on HD patient characteristics measured at...

  • Safety and efficacy of a continuous infusion, patient controlled anti-emetic pump to facilitate outpatient administration of high-dose chemotherapy. Dix, S P; Cord, M K; Howard, S J; Coon, J L; Belt, R J; Geller, R B // Bone Marrow Transplantation;9/1/99, Vol. 24 Issue 5, p561 

    We evaluated the combination of diphenhydramine, lorazepam, and dexamethasone delivered as a continuous i.v. infusion via an ambulatory infusion pump with patient-activated intermittent dosing (BAD pump) for prevention of acute and delayed nausea/vomiting in patients receiving high-dose...

  • Ex vivo expansion of megakaryocyte precursor cells in autologous stem cell transplantation for relapsed malignant lymphoma. Decaudin, D.; Vantelon, J.-M.; Bourhis, J.-H.; Farace, F.; Bonnet, M.-L.; Guillier, M.; Greissenger, N.; Marracho, M.-C.; Assari, S.; Bennaceur, A.-L.; Némati, F.; Michon, J.; Turhan, A. G.; Boccaccio, C. // Bone Marrow Transplantation;Dec2004, Vol. 34 Issue 12, p1089 

    Summary:To evaluate the impact of ex vivo expanded megakaryocyte (MK) progenitors on high-dose chemotherapy-induced thrombocytopenia, we conducted a phase II study in 10 patients with relapsed lymphoma. Two fractions of peripheral blood progenitor cells (PBPC) were cryopreserved, one with enough...

  • High-dose thiotepa, melphalan and carboplatin (TMCb) followed by autologous peripheral blood stem cell transplantation in patients with lymphoma-a retrospective evaluation. Demirer, T; Ayli, M; Fen, T; Ozcan, M; Arat, M; Buyukberber, S; Arslan, O; Gurman, G; Akan, H; Ilhan, O // Bone Marrow Transplantation;Nov2004, Vol. 34 Issue 9, p781 

    Summary:The purpose of this evaluation was to investigate the efficacy of high-dose chemotherapy with thiotepa, melphalan, and carboplatin (TMCb), and of autologous peripheral blood stem cell (PBSC) infusion in patients with aggressive non-Hodgkin's lymphoma (NHL) or Hodgkin's disease (HD). A...

  • Keys to a canine bone-marrow transplant.  // DVM: The Newsmagazine of Veterinary Medicine;Jul2008, Vol. 39 Issue 7, p16S 

    The article presents an overview of the process involved in a canine bone-marrow transplant. Staging is initiated to specify the type of lymphoma and testing is performed to identify a molecular marker. A three-week period is required after the last dose of chemotherapy and a donor patient is...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics